How LONSURF +/- bevacizumab works

LONSURF is an antimetabolite combination agent.1,2

  • Trifluridine (FTD) is a fluorinated thymidine analogue incorporated into the DNA, causing DNA dysfunction that leads to the death of cancer cells1,3*
    • FTD is not a prodrug of 5-fluorouracil (5-FU)4
  • Tipiracil (TPI) inhibits the rapid degradation of FTD1

Bevacizumab is a vascular endothelial growth factor (VEGF) inhibitor.5

  • VEGF inhibitors prevent angiogenesis (the growth of new blood vessels) by selectively binding to circulating VEGF and thus inhibiting the binding of VEGF to its cell surface receptors (VEGFR)5-7

Proposed mechanism of action (MOA)1,3-8

LONSURF interferes with DNA synthesis and prevents cell proliferation, while bevacizumab starves the tumor by preventing angiogenesis.1,7

Mechanism of action diagram showing trifluridine incorporation into DNA, tipiracil increasing trifluridine levels, and bevacizumab binding VEGF to inhibit angiogenesis.

This presentation is for illustrative purposes only.

Not intended to imply clinical significance.

*LONSURF can also have toxic effects on healthy, nontumor cells.